Artykuły w czasopismach na temat „Facteur VIII (FVIII)”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „Facteur VIII (FVIII)”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.
Labrouche, S., C. Vergnes, J. Constans, A. Berard i G. Freyburger. "Augmentation du facteur VIII (FVIII) : recherche d’une implication moléculaire du LRP". Journal des Maladies Vasculaires 30, nr 4 (wrzesień 2005): 6. http://dx.doi.org/10.1016/s0398-0499(05)86244-4.
Pełny tekst źródłaYada, Koji, Kenichi Ogiwara, Masaru Shibata, Midori Shima i Keiji Nogami. "Effects of anti-factor VIII inhibitor antibodies on factor VIIa/tissue factor-catalysed activation and inactivation of factor VIII". Thrombosis and Haemostasis 105, nr 06 (2011): 989–98. http://dx.doi.org/10.1160/th10-12-0781.
Pełny tekst źródłaYada, Koji, Keiji Nogami, Kenichi Ogiwara, Katsumi Nishiya, Masahiro Takeyama i Midori Shim. "Effects of Anti-FVIII Inhibitors On Factor VIIa/Tissue Factor-Catalyzed Activation and Inactivation of Factor VIII." Blood 114, nr 22 (20.11.2009): 3169. http://dx.doi.org/10.1182/blood.v114.22.3169.3169.
Pełny tekst źródłaNakajima, Yuto, Koji Yada, Keiji Nogami i Midori Shima. "A Novel Mechanism of Factor VIIa/Tissue Factor (TF)-Catalyzed Activation and Inactivation of B-Domain-Deleted Factor VIII in the Early Initiation Phases of Coagulation". Blood 132, Supplement 1 (29.11.2018): 1162. http://dx.doi.org/10.1182/blood-2018-99-115645.
Pełny tekst źródłaOgiwara, Kenichi, Keiji Nogami, Masahiro Okuda, Katsumi Nishiya, Masahiro Takeyama i Midori Shima. "Interactions of Factor VIII with Tissue Factor Contributes to the Acceleration of Factor Xa Generation in the Initiation Phase of Blood Coagulation." Blood 114, nr 22 (20.11.2009): 3177. http://dx.doi.org/10.1182/blood.v114.22.3177.3177.
Pełny tekst źródłaOgiwara, Kenichi, Keiji Nogami, Tetsuhiro Soeda, Tomoko Matsumoto, Katsumi Nishiya i Midori Shima. "Mechanisms of Factor VIII Activation by Recombinant Factor VIIa Analog through Tissue Factor-Independent Manner". Blood 112, nr 11 (16.11.2008): 1028. http://dx.doi.org/10.1182/blood.v112.11.1028.1028.
Pełny tekst źródłaSoeda, Tetsuhiro, Keiji Nogami, Tomoko Matsumoto, Kenichi Ogiwara, Katsumi Nishiya i Midori Shima. "Tissue Factor-Dependent Activation of Factor VIII by Factor VIIa in the Early Phase of Blood Coagulation". Blood 112, nr 11 (16.11.2008): 1036. http://dx.doi.org/10.1182/blood.v112.11.1036.1036.
Pełny tekst źródłaShoko, Furukawa, Keiji Nogami, Kenichi Ogiwara i Midori Shima. "Mechanism of Tissue Factor (TF) Enhancing Factor (F)VIII Activity on FXa Generation in Initial Phase of Coagulation and Interaction Between TF and FVIII C2 Domain". Blood 128, nr 22 (2.12.2016): 1391. http://dx.doi.org/10.1182/blood.v128.22.1391.1391.
Pełny tekst źródłaRadtke, Klaus-Peter, Dean Chamberlain, John H. Griffin i Andrew J. Gale. "Whole Blood Thromboelastogram Assays Demonstrate Prolonged Factor VIIIa Potency for Recombinant Disulfide Bond-Stabilized Factor VIII Variants." Blood 104, nr 11 (16.11.2004): 2976. http://dx.doi.org/10.1182/blood.v104.11.2976.2976.
Pełny tekst źródłaMeeks, Shannon, Ernest T. Parker, Amy L. Dunn, John F. Healey i Pete Lollar. "Proteolytically Inactivatable Factor VIII is Less Immunogenic than Factor VIII in a Murine Hemophilia A Model." Blood 114, nr 22 (20.11.2009): 27. http://dx.doi.org/10.1182/blood.v114.22.27.27.
Pełny tekst źródłaYada, Koji, Keiji Nogami, Kenichi Ogiwara i Midori Shima. "A novel mechanism of Enhancing the Haemostatic Effect in the Combination with Recombinant Factor VIII and Activated Prothrombin Complex Concentrate(APCC) in Hemophilia A Patients with Inhibitor". Blood 118, nr 21 (18.11.2011): 1178. http://dx.doi.org/10.1182/blood.v118.21.1178.1178.
Pełny tekst źródłaMesser, Amanda S., Barbara Ulmasov, Yogesh Kumar, Kanagasabai Vadivel, Degang Zhong, Philip Fay i S. Paul Bajaj. "Epitope Mapping of a Monoclonal Antibody to Factor VIII That Inhibits Factor IXa:Factor VIIIa Interaction and Thrombin Activation of Factor VIII". Blood 118, nr 21 (18.11.2011): 1177. http://dx.doi.org/10.1182/blood.v118.21.1177.1177.
Pełny tekst źródłaZakas, Philip, Kristopher Knight, Ernest T. Parker, H. Trent Spencer, Eric Gaucher i Christopher B. Doering. "Bioengineering Coagulation Factor VIII through Ancestral Protein Reconstruction". Blood 126, nr 23 (3.12.2015): 123. http://dx.doi.org/10.1182/blood.v126.23.123.123.
Pełny tekst źródłaOkayama, Yusuke, Masato Bingo, Kazuki Sakatoku, Hiroshi Okamura, Satoru Nanno, Mitsutaka Nishimoto, Yasuhiro Nakashima, Hideo Koh, Masayuki Hino i Hirohisa Nakamae. "The safety of the combination therapy of recombinant factor VIIa and plasma-derived factor VIIa and factor X for refractory hemorrhage in acquired hemophilia A". Blood Coagulation & Fibrinolysis 34, nr 6 (19.07.2023): 419–22. http://dx.doi.org/10.1097/mbc.0000000000001243.
Pełny tekst źródłaOgiwara, Kenichi, Midori Shima i Keiji Nogami. "Factor VIII activation by factor VIIa analog (V158D/E296V/M298Q) in tissue factor-independent mechanisms". Thrombosis and Haemostasis 106, nr 10 (2011): 665–74. http://dx.doi.org/10.1160/th11-04-0264.
Pełny tekst źródłaRao, LV, i SI Rapaport. "Factor VIIa-catalyzed activation of factor X independent of tissue factor: its possible significance for control of hemophilic bleeding by infused factor VIIa". Blood 75, nr 5 (1.03.1990): 1069–73. http://dx.doi.org/10.1182/blood.v75.5.1069.1069.
Pełny tekst źródłaRao, LV, i SI Rapaport. "Factor VIIa-catalyzed activation of factor X independent of tissue factor: its possible significance for control of hemophilic bleeding by infused factor VIIa". Blood 75, nr 5 (1.03.1990): 1069–73. http://dx.doi.org/10.1182/blood.v75.5.1069.bloodjournal7551069.
Pełny tekst źródłaMinami, Hiroaki, Keiji Nogami, Takehisa Kitazawa, Kunihiro Hattori i Midori Shima. "FVIII Heavy Chain Enhances Tenase Activity Induced By FVIIIa Mimicking Bispesific Antibody, ACE910". Blood 124, nr 21 (6.12.2014): 1481. http://dx.doi.org/10.1182/blood.v124.21.1481.1481.
Pełny tekst źródłaDoshi, Bhavya, Courtney Cox, Bagirath Gangadharan, Christopher B. Doering i Shannon L. Meeks. "Factor VIII Supplementation Improves Recombinant VIIa Initiated Thrombin Generation in Hemophilia A Inhibitor Patient Plasmas". Blood 118, nr 21 (18.11.2011): 28. http://dx.doi.org/10.1182/blood.v118.21.28.28.
Pełny tekst źródłaWilhelm, Amelia R., Nicole A. Parsons, Benjamin J. Samelson-Jones, Robert J. Davidson, Charles T. Esmon, Rodney M. Camire i Lindsey A. George. "Activated protein C has a regulatory role in factor VIII function". Blood 137, nr 18 (6.05.2021): 2532–43. http://dx.doi.org/10.1182/blood.2020007562.
Pełny tekst źródłaGale, Andrew J., Diana Rozenshteyn i Justin Riceberg. "The Neutrophil Proteases, Elastase and Cathepsin G, May Modulate the Activity of Factor VIII." Blood 108, nr 11 (16.11.2006): 1716. http://dx.doi.org/10.1182/blood.v108.11.1716.1716.
Pełny tekst źródłaYada, Koji, i Keiji Nogami. "Novel Insights and New Developments Regarding Coagulation Revealed by Studies of the Anti-Factor IXa (Activated Factor IX)/Factor X Bispecific Antibody, Emicizumab". Arteriosclerosis, Thrombosis, and Vascular Biology 40, nr 5 (maj 2020): 1148–54. http://dx.doi.org/10.1161/atvbaha.120.312919.
Pełny tekst źródłaAddiego, Joseph E., Edward Gomperts, Liu Shu-Len, Patricia Bailey, Suzanne G. Courter, Martin L. Lee, Gerald G. Neslund, Henry S. Kingdon i Michael J. Griffith. "Treatment of Hemophilia A with a Highly Purified Factor VIII Concentrate Prepared by Anti-FVIIIc Immunoaffinity Chromatography". Thrombosis and Haemostasis 67, nr 01 (1992): 019–27. http://dx.doi.org/10.1055/s-0038-1648373.
Pełny tekst źródłaNeuenschwander, Pierre F. "Evidence of Abnormal Coagulation: Production of Factor VIII α-Fragment In Vivo." Blood 106, nr 11 (16.11.2005): 1020. http://dx.doi.org/10.1182/blood.v106.11.1020.1020.
Pełny tekst źródłaBloem, Esther, Henriet Meems, Maartje van den Biggelaar, Koen Mertens i Alexander B. Meijer. "Factor VIII Region 1811–1818 Is Involved in Factor IXa Binding and Factor VIIIa Stability". Blood 120, nr 21 (16.11.2012): 3357. http://dx.doi.org/10.1182/blood.v120.21.3357.3357.
Pełny tekst źródłaWilhelm, Amelia R., Nicole A. Parsons, Charles T. Esmon, Rodney M. Camire i Lindsey A. George. "In Vivo hemostatic Significance of Activated Protein C in Factor VIIIa Regulation". Blood 134, Supplement_1 (13.11.2019): 93. http://dx.doi.org/10.1182/blood-2019-124493.
Pełny tekst źródłaHealey, John F., Ernest Parker i John (Pete) S. Lollar. "Comparative Decay Rates of Human, Rhesus Macaque, Cynomolgus, and Porcine Activated Factor VIII." Blood 114, nr 22 (20.11.2009): 3164. http://dx.doi.org/10.1182/blood.v114.22.3164.3164.
Pełny tekst źródłaRozenshteyn, Diana, i Andrew J. Gale. "Cathepsin G, a leukocyte protease, activates coagulation factor VIII". Thrombosis and Haemostasis 99, nr 01 (2008): 44–51. http://dx.doi.org/10.1160/th07-08-0495.
Pełny tekst źródłavan 't Veer, C., TM Hackeng, C. Delahaye, JJ Sixma i BN Bouma. "Activated factor X and thrombin formation triggered by tissue factor on endothelial cell matrix in a flow model: effect of the tissue factor pathway inhibitor". Blood 84, nr 4 (15.08.1994): 1132–42. http://dx.doi.org/10.1182/blood.v84.4.1132.1132.
Pełny tekst źródłavan 't Veer, C., TM Hackeng, C. Delahaye, JJ Sixma i BN Bouma. "Activated factor X and thrombin formation triggered by tissue factor on endothelial cell matrix in a flow model: effect of the tissue factor pathway inhibitor". Blood 84, nr 4 (15.08.1994): 1132–42. http://dx.doi.org/10.1182/blood.v84.4.1132.bloodjournal8441132.
Pełny tekst źródłaMazurier, Claudine, Armelle Parquet-Gernez i Maurice Goudemand. "Validation of a Procedure for Potency Assessing of a High Purity Factor VIII Concentrate -Comparison of Different Factor VIII Coagulant Assays and Effect of Prediluent". Thrombosis and Haemostasis 64, nr 02 (1990): 251–55. http://dx.doi.org/10.1055/s-0038-1647295.
Pełny tekst źródłaTakeyama, Masahiro, Keiji Nogami, Tomoko Matsumoto, Tetsuhiro Soeda, Tsukasa Suzuki, Kunihiro Hattori i Midori Shima. "Characterisation of an antibody specific for coagulation factor VIII that enhances factor VIII activity". Thrombosis and Haemostasis 103, nr 01 (2010): 94–102. http://dx.doi.org/10.1160/th09-05-0338.
Pełny tekst źródłaPeerlinck, Kathelijne, Marc G. Jacquemin, Jef Arnout, Marc F. Hoylaerts, Jean Guy G. Gilles, Renaud Lavend’homme, Karen M. Johnson i in. "Antifactor VIII Antibody Inhibiting Allogeneic but not Autologous Factor VIII in Patients With Mild Hemophilia A". Blood 93, nr 7 (1.04.1999): 2267–73. http://dx.doi.org/10.1182/blood.v93.7.2267.
Pełny tekst źródłaPeerlinck, Kathelijne, Marc G. Jacquemin, Jef Arnout, Marc F. Hoylaerts, Jean Guy G. Gilles, Renaud Lavend’homme, Karen M. Johnson i in. "Antifactor VIII Antibody Inhibiting Allogeneic but not Autologous Factor VIII in Patients With Mild Hemophilia A". Blood 93, nr 7 (1.04.1999): 2267–73. http://dx.doi.org/10.1182/blood.v93.7.2267.407k21_2267_2273.
Pełny tekst źródłaPonder, Katherine P. "FIXing Factor VIII inhibitors". Blood 119, nr 2 (12.01.2012): 325–26. http://dx.doi.org/10.1182/blood-2011-11-389486.
Pełny tekst źródłaZhong, Degang, Evgueni L. Saenko, Midori Shima, Matthew Felch i Dorothea Scandella. "Some Human Inhibitor Antibodies Interfere With Factor VIII Binding to Factor IX". Blood 92, nr 1 (1.07.1998): 136–42. http://dx.doi.org/10.1182/blood.v92.1.136.413k35_136_142.
Pełny tekst źródłaHsu, Ting-Chang, Kathleen P. Pratt i Arthur R. Thompson. "The factor VIII C1 domain contributes to platelet binding". Blood 111, nr 1 (1.01.2008): 200–208. http://dx.doi.org/10.1182/blood-2007-01-068957.
Pełny tekst źródłaGrushin, Kirill, Jaimy Miller, Daniela Dalm i Svetla Stoilova-McPhie. "Factor VIII organisation on nanodiscs with different lipid composition". Thrombosis and Haemostasis 113, nr 04 (lipiec 2015): 741–49. http://dx.doi.org/10.1160/th14-09-0725.
Pełny tekst źródłaHakeos, William, Hongzhi Miao, Nongnuch Sirachainan, Geoffrey Kemball-Cook, Evgueni Saenko, Randal Kaufman i Steven Pipe. "Hemophilia A Mutations within the Factor VIII A2-A3 Subunit Interface Destabilize Factor VIIIa and Cause One-stage/ Two-stage Activity Discrepancy". Thrombosis and Haemostasis 88, nr 11 (2002): 781–87. http://dx.doi.org/10.1055/s-0037-1613302.
Pełny tekst źródłaStrijbis, Viola J. F., Ka Lei Cheung, Pavlina Konstantinova, Ying Poi Liu, Sander J. van Deventer i Mettine H. A. Bos. "Evaluation of a Blood Coagulation Factor IX Variant That Functions Independently of Factor VIII As an Alternative Treatment for Hemophilia A". Blood 134, Supplement_1 (13.11.2019): 1110. http://dx.doi.org/10.1182/blood-2019-124120.
Pełny tekst źródłaSen, Prosenjit, Curtis A. Clark, Ramakrishnan Gopalakrishnan, Ulla Hedner, Charles T. Esmon, Usha R. Pendurthi i L. Vijaya Rao. "Factor VIIa binding to endothelial cell protein C receptor: Differences between mouse and human systems". Thrombosis and Haemostasis 107, nr 05 (2012): 951–61. http://dx.doi.org/10.1160/th11-09-0672.
Pełny tekst źródłaLannert, Kerry W., Hilary S. Gammill, Barbara A. Konkle i Jill M. Johnsen. "The Ability of Von Willebrand Factor (VWF) to Bind Factor VIII (FVIII) Can Decrease during Pregnancy". Blood 124, nr 21 (6.12.2014): 4244. http://dx.doi.org/10.1182/blood.v124.21.4244.4244.
Pełny tekst źródłaRolli, Veronique, Nathalie Enjolras, Cecile Ducasse, Marie-Helene Rodriguez, Thomas Weimer, Hans-Peter Hauser, Claude Negrier i Jean-Luc Plantier. "Generation of Factor VIII Molecules Partially Resistant to Activated Protein C." Blood 104, nr 11 (16.11.2004): 1729. http://dx.doi.org/10.1182/blood.v104.11.1729.1729.
Pełny tekst źródłaMarkovitz, Rebecca C., John F. Healey, Ernest T. Parker, Shannon L. Meeks i Pete Lollar. "The diversity of the immune response to the A2 domain of human factor VIII". Blood 121, nr 14 (4.04.2013): 2785–95. http://dx.doi.org/10.1182/blood-2012-09-456582.
Pełny tekst źródłaGolino, Paolo, Massimo Ragni, Plinio Cirillo, Annalisa Scognamiglio, Amelia Ravera, Chiara Buono, Angela Guarino i in. "Recombinant human, active site-blocked factor VIIa reduces infarct size and no-reflow phenomenon in rabbits". American Journal of Physiology-Heart and Circulatory Physiology 278, nr 5 (1.05.2000): H1507—H1516. http://dx.doi.org/10.1152/ajpheart.2000.278.5.h1507.
Pełny tekst źródłaJenkins, P. Vincent, Jan Freas, Kyla M. Schmidt, Qian Zhou i Philip J. Fay. "Mutations associated with hemophilia A in the 558-565 loop of the factor VIIIa A2 subunit alter the catalytic activity of the factor Xase complex". Blood 100, nr 2 (15.07.2002): 501–8. http://dx.doi.org/10.1182/blood-2001-12-0361.
Pełny tekst źródłaWakabayashi, Hironao, Jennifer Wintermute i Philip J. Fay. "Stabilizing Factor VIIIa By Combining Mutations That Modulate Inter-Subunit Interactions and Proteolytic Inactivation". Blood 122, nr 21 (15.11.2013): 3572. http://dx.doi.org/10.1182/blood.v122.21.3572.3572.
Pełny tekst źródłaGangadharan, Bagirath, H. Trent Spencer, Ernest T. Parker i Christopher B. Doering. "High-Level Expression of Porcine Factor VIII from Murine Mesenchymal Stem Cells." Blood 104, nr 11 (16.11.2004): 5281. http://dx.doi.org/10.1182/blood.v104.11.5281.5281.
Pełny tekst źródłaCooper, Adrian, Zhong Liang, Francis Castellino i Elliot Rosen. "Cloning and Characterization of the Murine Coagulation Factor X Gene". Thrombosis and Haemostasis 83, nr 05 (2000): 732–35. http://dx.doi.org/10.1055/s-0037-1613901.
Pełny tekst źródłaOgiwara, Kenichi, Tomoko Matsumoto, Katsumi Nishiya, Masahiro Takeyama, Midori Shima i Keiji Nogami. "Mechanisms of human neutrophil elastase-catalysed inactivation of factor VIII(a)". Thrombosis and Haemostasis 105, nr 06 (2011): 968–80. http://dx.doi.org/10.1160/th10-12-0777.
Pełny tekst źródła